99% of national commercial,
Medicare Part D, and Medicaid
patients have access to
HUMIRA as a preferred,
first‑line† TIM‡ on formulary2,§
HUMIRA Complete offers
one-on-one attention,
helping patients start and
stay on track with their
prescribed treatment plan
*Day 1 starts after required prior authorization.
†Formulary Definitions: Preferred/Step 1 means the product is placed on the plan’s preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit,
or are placed on a higher tier. First-line refers to a preferred or parity formulary status.
‡A TIM (targeted immunomodulator) is a pharmacologic agent that modifies the immune response by targeting certain mediators or select cell surface markers on immune cells.
§Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
Not actual patients.
2020 National Commercial, Medicare Part D, and Medicaid Access
In 2020, 99% of national commercial, Medicare Part D, and
Medicaid patients have access to HUMIRA as a preferred, first-line† TIM‡ on formulary.2,§
In 2019, 94% of eligible, commercially
insured HUMIRA Complete Savings
Card users received their HUMIRA for $5 per month, every month.3,||
*Day 1 starts after required prior authorization.
†Formulary Definitions: Preferred/Step 1 means the product is placed on the plan’s preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit, or are placed on a higher tier. First-line refers to a preferred or parity formulary status.
‡A TIM (targeted immunomodulator) is a pharmacologic agent that modifies the immune response by targeting certain mediators or select cell surface markers on immune cells.
§Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
IITerms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
Arava and Plaquenil are registered trademarks of their respective owners.
Help them start and stay on track with their treatment plan. HUMIRA Complete provides your patients with the resources they need, when they need them, throughout their whole treatment journey – and at no additional cost to them.
Resources designed with patients in mind
One-step enrollment: simple for patients
Here’s how to enroll…
Enrollment Fax Form
1.800.4HUMIRA (1.800.448.6472)
HUMIRA Complete Pro
*Ambassadors do not provide medical advice and are trained to direct patients to speak with their healthcare professional about any treatment-related questions, including further referrals.
Tomorrow
A Nurse Ambassador is personally
assigned to your patient and
calls within 1 business day
As Soon As Possible
Explains to your patients how to navigate
the insurance process and identify ways
to help save on the cost of HUMIRA
Provides ongoing supplemental injection
training, in-person or over-the-phone
Empowers patients with disease state
education to equip them with the knowledge
needed to understand their disease journey
Moving Forward
Answers questions that come up
and
offers continuing guidance
>1.6 MILLION
personalized, one-to-one discussions with patients.
That’s over 281,500 in 2019 alone.4
HUMIRA Complete Nurses are
available 24/7†
Your patients can reach out to their
nurse by calling 1.800.4HUMIRA (1.800.448.6472)
Your patients can reach out to their
nurse by calling 1.800.4HUMIRA (1.800.448.6472)
Sharps disposal containers and a
mail-back service are provided by
HUMIRA Complete for
your patients’
used Pens or syringes
HUMIRA Nurse Ambassadors: Empowering Patients
Navigating the Challenge of Insurance
Complete Pro is an online resource designed to help your patients obtain their prescription in a timely manner.
You can choose the capabilities that are most relevant to you and your patients’ needs, such as:
Instant benefits verification
Online prescribing efficiencies
Visit Complete Pro to register your patients
†Nurses are available at 1.800.4HUMIRA (1.800.448.6472) for immediate assistance Monday through Friday, from 8 AM to 8 PM ET. At all other times, a nurse will return calls
within 1 hour.
In a retrospective claims analysis,
HUMIRA Complete helped patients get started on therapy faster, helped to increase refill adherence, and helped them to continue therapy longer5,6,*
FASTER ON THERAPY
GREATER REFILL ADHERENCE
LONGER TIME ON THERAPY
Patients filled their first prescription
TWICE AS FAST when prescription
was initiated through HUMIRA Complete Pro
(HCPro)5,*
HCPro Patients
7
DAYSa
(n=299)
Non-HCPro Patients
14
DAYS
(n=13,611)
aP<0.0001, HCPro Patients vs Non-HCPro Patients.
*Based on retrospective studies using patient-level data from HUMIRA Complete.
Study Objective:5
To evaluate the impact of HCPro on HUMIRA treatment initiation:
Study Design Summary:5
Patient-level HCPro data for an FDA-approved indication were combined with Symphony Health Solutions claims for patients initiating HUMIRA between 01/2012 and 04/2015. The retrospective sample included commercially‑insured patients aged ≥ 18 years with a diagnosis of RA, PsA, AS, CD, UC, and Ps. Time to first fill was compared between patients who initiated prescription process through HCPro (n=299) and those who did not (n=13,611).
Limitations:5
Enrolled patients had 29.3% HIGHER (relative difference) refill adherence over one year vs patients not enrolled6,*
Enrolled Patients
64.8%a
(n=1,134)
Non-enrolled Patients
50.1%
(n=1,134)
Mean refill adherence measured by Proportion of Days Covered (PDC) was higher for the HUMIRA Complete cohort vs the non-HUMIRA Complete cohort at 12 months (P<0.0001).6,†
aP<0.0001, Enrolled Patients vs non-enrolled patients.
*Based on retrospective studies using patient-level data from HUMIRA Complete.
†P-value based on two-sample t-test of means. Relative difference calculated as Patient Support Program (PSP) – Non-PSP/Non-PSP.
Study Objective:6
To compare prescription refill adherence based on enrollment in HUMIRA Complete among commercially‑insured patients.
Study Design Summary:6,7
A longitudinal retrospective study (N=2,268) was conducted for an FDA-approved indication using patient‑level data from HUMIRA Complete linked with Symphony Health Solutions claims.
Commercially‑insured biologic-naïve patients aged ≥18 years initiating HUMIRA between 01/2015 to 02/2016 (index date) were included. Patients who participated with HUMIRA Complete were matched to those who did not. Refill adherence as measured by proportion of days covered (PDC) was assessed over the following 12 months.
Limitations:6,7
Patients continued refilling 22.6% LONGER WHEN ENROLLED IN HUMIRA COMPLETE vs non‑enrolled patients over one year6,*
Mean 266 days vs 217 days, P<0.0001.
*Refill discontinuation was defined as a gap in the filling of pharmacy claims for HUMIRA treatment greater than the days of supply on the patient’s last claim without any further HUMIRA prescription or switching to another biologic medication.
Study Objective:6
To compare refill discontinuation based on enrollment in HUMIRA Complete among commercially‑insured patients.
Study Design Summary:6,7
A longitudinal retrospective study (N=2,268) was conducted for an FDA-approved indication using patient‑level data from HUMIRA Complete linked with Symphony Health Solutions claims.
Commercially‑insured biologic-naïve patients aged ≥18 years initiating HUMIRA between 01/2015 to 02/2016 (index date) were included. Patients who participated with HUMIRA Complete were matched to those who did not. Refill discontinuation was assessed over the following 12 months.
Limitations:6,7
AS=ankylosing spondylitis; CD=Crohn’s disease; Ps=plaque psoriasis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; UC=ulcerative colitis
Pediatric Crohn’s Disease: HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6‑mercaptopurine, or methotrexate.
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue HUMIRA if a patient develops a serious infection or sepsis.
Reported infections include:
Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T‑cell lymphoma (HSTCL), a rare type of T‑cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6‑mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.
Rheumatoid Arthritis: HUMIRA is indicated, alone or in combination with methotrexate or other non-biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Juvenile Idiopathic Arthritis: HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Psoriatic Arthritis: HUMIRA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
Ankylosing Spondylitis: HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
Crohn’s Disease: HUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
Ulcerative Colitis: HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.
Limitations of Use:
The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.
Plaque Psoriasis: HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
Hidradenitis Suppurativa: HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
Uveitis: HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
US-HUM-210183
Please see full Prescribing Information.
References: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc. 2. Data on File, AbbVie Inc. Payer-reported lives. December 2019. 3. Data on File, AbbVie Inc. ZS Associates Analysis of OPUS Health Claims Data. June 2019. 4. Data on File, AbbVie Inc. HUMIRA Complete Metrics, August 2019. 5. Data on File, AbbVie Inc. H16.DOF.028. 6. Brixner D, Rubin OT, Mease P, et al. Benefits of a patient support program on adherence, discontinuation, and costs in the U.S. commercial population of adalimumab‑treated patients. Abstract presented at the Academy of Managed Care Pharmacy (AMCP). April 23–26, 2018; Boston, MA. 7. Data on File, AbbVie Inc. H17.DOF.058.